Evidence map›Paper›PMID 37679594›Full record

ArticleEJNMMI radiopharmacy and chemistry2023

Development of [

Ashleigh Hull, William Hsieh, Artem Borysenko, William Tieu, Dylan Bartholomeusz, Eva Bezak

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Progress in the application ofAnnals of nuclear medicine · 2026
    Review
  2. Review
  3. Article
  4. Mucin-Targeted Antibodies for Ovarian Cancer.Seminars in nuclear medicine · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ashleigh HullAllied Health and Human Performance Academic Unit, University of South Australia, City East Campus, Cnr North Tce and Frome Road, Adelaide, SA, 5001, Australia. ashleigh.hull@unisa.edu.au.ORCID http://orcid.org/0000-0003-3361-997X
William HsiehAllied Health and Human Performance Academic Unit, University of South Australia, City East Campus, Cnr North Tce and Frome Road, Adelaide, SA, 5001, Australia.ORCID http://orcid.org/0000-0002-7161-4152
Artem BorysenkoRadiation Protection Branch, South Australian Environment Protection Authority, Adelaide, SA, 5000, Australia.
William TieuSchool of Physical Sciences, The University of Adelaide, Adelaide, SA, 5000, Australia.
Dylan BartholomeuszDepartment of PET, Nuclear Medicine & Bone Densitometry, Royal Adelaide Hospital, SA Medical Imaging, Adelaide, SA, 5000, Australia.
Eva BezakAllied Health and Human Performance Academic Unit, University of South Australia, City East Campus, Cnr North Tce and Frome Road, Adelaide, SA, 5001, Australia.ORCID http://orcid.org/0000-0002-1315-1735
Royal Adelaide Hospital · AUThe University of Adelaide · AUUniversity of South Australia · AU

Funding

Australian Government Research Training Program ScholarshipAustralian Nuclear Science and Technology Organisation 2021 ANSTO/ANZSNM Research GrantPanKind, The Australian Pancreatic Cancer Foundation 2019 Avner Innovation Grant
6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy which may benefit from radioimmunotherapy. Previously, [

resultsCell binding and internalisation of [

conclusion[

Indexed as

Actinium-225MUC1Pancreatic ductal adenocarcinomaRadioimmunotherapy

Identifiers

PMID37679594
PMCPMC10484829
OpenAlexW4386494410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.